Overview
Updated 14 Jul 2026
Pasi A. Jänne, MD PHD, is Senior Vice President for Translational Medicine at Dana-Farber Cancer Institute (academic affiliation: Harvard Medical School). The public record shows 2,385 publications with 127,638 citations (h-index 163), centered on Lung Cancer Treatments and Mutations, Cancer Genomics and Diagnostics, Lung Cancer Research Studies. It also documents an investigator role on 15 registered clinical trials, industry payments reported by 30 companies, 10 NIH-funded awards (2008–2025).
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Lung Cancer Treatments and Mutations
- 15 registered trials on ClinicalTrials.gov
- Open Payments reporting from 30 companies
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Drugs & moleculesacross trials, industry payments and publications
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 60 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 583.
Clinical & industrytrials, payments and federal funding
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 15 registered studies on ClinicalTrials.gov. The most recent:
- Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Sponsor: SystImmune Inc.
InvestigatorPhase 1RecruitingNCT05983432 - Biology of Young Lung Cancer Study: The YOUNG LUNG Study
Sponsor: Dana-Farber Cancer Institute
InvestigatorRecruitingNCT05265429 - A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
Sponsor: Dana-Farber Cancer Institute
InvestigatorPhase 2Active, not recruitingNCT03392246
Industry payments
Updated 14 Jul 2026
30 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- GlaxoSmithKline, LLC.Program year20254 payments$21,922openpaymentsdata.cms.gov ↗
- Merck Sharp & Dohme LLCProgram year202510 payments$21,614openpaymentsdata.cms.gov ↗
- E.R. Squibb & Sons, L.L.C.Program year20254 payments$12,975openpaymentsdata.cms.gov ↗
NIH funding
Updated 14 Jul 2026
10 NIH research awards on record, funded 2008–2025 per NIH RePORTER. The latest:
- Development of Combination Therapies to Delay/Prevent Acquired Drug Resistance
Dana-Farber Cancer Inst
FY2024$995,148R35CA220497
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor Against Uncommon EGFR Mutations.
Molecular cancer therapeutics
2026 - Presenting Features and Causes of Diagnostic Delays: A Report From the NUT Carcinoma Registry.
JCO precision oncology
2025
Most-cited worksby citation count (OpenAlex)
- 01
- 02Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer4,505 citations2010
- 03
- 04The landscape of somatic copy-number alteration across human cancers4,138 citations2010
- 05
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Network
Updated 14 Jul 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →biocartis.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- Residency
Internal Medicine, Brigham and Women's Hospital
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - Fellowship
Hematology & Oncology, Dana-Farber/Partners CancerCare
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Editorial & leadership rolesjournal and society appointments
- Co-Leader
Lung Cancer Program, Dana-Farber/Harvard Cancer Center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗ - Editor
Clinical Cancer Research (AACR journal)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aacrjournals.org ↗
Awards & honorshonors on the public record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pressroom.cancer.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗
Secondary affiliationsappointments beyond the home institution
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →tolremo.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →frontiermeds.com ↗
- Director
Chen-Huang Center for EGFR Mutant Lung Cancers, Dana-Farber Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Media & interviewspress, podcasts and appearances
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lungcancerstoday.com ↗
- Recurring video/author contributor
OncLive (interviews and expert perspectives on EGFR-mutant NSCLC, FLAURA2 trial, etc.)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accountspublic accounts run by this person
- Doximity
doximity.com/pub/pasi-janne-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Pasi-A-Jaenne-39074779
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - ResearchGate
researchgate.net/scientific-contributions/Pasi-A-Janne-11783151
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by otherswhere others cite or feature them
- LinkedIn
linkedin.com/posts/dana-farber-cancer-institute_pasi-j%C3%A4nne-md-phd-is-the-first-incumbent-activity-7028433687176171521-53Zr
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - Other
cancerletter.com/podcastc/20250214_5
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancerletter.com ↗ - Other
oncodaily.com/dialogues/oncoinfluencers-pasi-a-janne-dialogue
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncodaily.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Paul Richardson, MD
Harvard University
- 2,062
- publications
- 172
- h-index
- 17
- trials
Steven Greenberg, MD
Harvard University
- 954
- publications
- 144
- h-index
- 9
- trials
David Scadden, MD
Harvard University
- 665
- publications
- 124
- h-index
- 4
- trials
David Reardon, MD
Harvard University
- 1,226
- publications
- 121
- h-index
- 28
- trials